Stopping immunotherapy after 2 years may not increase mortality risk in lung cancer.
Stopping immunotherapy after 2 years may not increase mortality risk in lung cancer.
Is Two Years of Immunotherapy Enough for Late-Stage Lung Cancer Patients?
Written by [Your Name]
Published on [Date]
Image Source: Westend61/Getty Images
For people with late-stage non-small cell lung cancer (NSCLC) undergoing initial immunotherapy treatment, a key question has been how long they should continue the therapy for the best chance at survival. A recent retrospective study examined medical records to compare the outcomes of people who stopped immunotherapy around the two-year mark with those who continued beyond that point. The findings suggest that stopping treatment after two years doesn’t seem to negatively affect survival rates, potentially offering reassurance to patients and healthcare providers contemplating whether to discontinue the treatment at that stage.
Recent research published in the journal JAMA Oncology is providing perspective on how long treatment with immune checkpoint inhibitor drugs should be given to people with late-stage non-small cell lung cancer (NSCLC). In particular, researchers investigated whether stopping the immunotherapy treatments after two years affects how long a patient will live.
- High cost deters people from getting COVID testing, which is concer...
- Breast milk improves babies’ microbiome health.
- Many Americans lack access to neurologists due to geographical dist...
In their study, the researchers looked at medical records of adults diagnosed with late-stage NSCLC between 2016 and 2020 and started their treatment with immunotherapy. The study focused on two different treatment paths: one where treatment was stopped at around two years (specifically between 700 and 760 days), and another where treatment continued for more than two years (more than 760 days). The main objective was to see how long people lived after the 760-day mark using specific statistical models.
What Researchers Learned in the Lung Cancer Treatment Study
Out of 1,091 people who were still receiving immunotherapy for the initial two years, there were two main groups: one that stopped treatment around the two-year mark (113 people), and one that kept going with the treatment (593 people). People in the group that stopped treatment were generally around 69 years old. Most of them were women and white. This group also had more smokers and were more likely to be treated at a university hospital.
When looking at how long people lived after the two-year point, researchers reported that about 79% of the group that stopped treatment were still alive, compared to 81% in the group that continued treatment. From a statistical perspective, the researchers said there was no meaningful difference in survival rates between the two groups. Furthermore, roughly one out of every five patients stopped immunotherapy at the two-year point even if their cancer hadn’t gotten worse.
The Debate Over Whether to Stop Immunotherapy Treatments
Dr. Lova Sun, MSCE, a lead author of the study who works in the Division of Hematology and Oncology in the Department of Medicine at the Perelman School of Medicine at the University of Pennsylvania, told Medical News Today that “a common clinical question for patients with metastatic non-small cell lung cancer with long-term response to immunotherapy-based treatment is how long to continue treatment.”
Dr. Haiying Cheng, an associate professor of oncology and medicine at the Albert Einstein College of Medicine as well as an oncologist at Montefiore Health System said that “immunotherapy has emerged as a significant breakthrough in the treatment of advanced NSCLC.” However, one question remains elusive: what is the ideal duration for immunotherapy? A two-year duration of immunotherapy has been commonly considered; however, a substantial number of patients opt to extend their treatment beyond this timeframe.
The study provides valuable real-world evidence, suggesting that a fixed duration of two years of immunotherapy may be sufficient for most patients who are progression-free at that point. This could potentially revolutionize how we approach treatment duration, moving away from indefinite treatment courses that come with their own set of challenges, such as increased toxicity and financial burden.
Reassurance but More Research Needed
Dr. Wael Harb, a hematologist and medical oncologist at Memorial Care Cancer Institute at Orange Coast Medical Center in California and vice president of medical Affairs at Syneos Health, said that “the paper by Sun et al. is both timely and impactful.” The implications of this research are multi-faceted and significant.
Firstly, it could lead to a more standardized approach to immunotherapy duration for NSCLC, which is beneficial for both clinicians and patients. Secondly, by potentially limiting the duration of immunotherapy to two years, we can reduce the risk of treatment-related adverse events, improving the patient’s quality of life. Lastly, there is the economic aspect; immunotherapy is expensive, and limiting the duration could result in substantial cost savings for healthcare systems and patients.
However, it’s important to note that while the study’s findings are promising, they are based on retrospective and observational data. Therefore, individualized treatment decisions should still be made considering various factors such as patient preferences, performance status, and specific tumor characteristics. Dr. Cheng emphasized the need for further research and validation through randomized prospective clinical trials.
In conclusion, the study provides reassurance that stopping immunotherapy for late-stage non-small cell lung cancer at two years does not compromise survival outcomes. It opens up the possibility of a more standardized and cost-effective approach to treatment duration, reducing toxicity and improving the patient’s quality of life. While further research is needed, these findings offer valuable insights into the debate surrounding the ideal duration of immunotherapy and its impact on NSCLC patients’ survival.
